Medullary Thyroid Cancer: Clinical Trials

3 trials for Medullary Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Active not recruiting 1, Completed 1, Withdrawn 1

Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3WithdrawnHoffmann-La Roche2023-11-302024-01-05
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3Active not recruitingLoxo Oncology, Inc.2912020-02-112026-03-19
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Patient outreach, Vandetanib - Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Phase 3CompletedSanofi2052011-02-252026-04-17

Narrower conditions

Carcinoma, Medullary (3)  ·  Neoplasm Metastasis (1)

Broader conditions

Adenocarcinoma (3)  ·  Carcinoma (3)  ·  Carcinoma, Neuroendocrine (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Ductal, Lobular, and Medullary (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neuroectodermal Tumors (3)  ·  Neuroendocrine Tumors (3)  ·  Neoplastic Processes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

vandetanib (3)  ·  cabozantinib (2)  ·  pralsetinib (1)  ·  selpercatinib (1)

Sponsors

Hoffmann-La Roche (1)  ·  Loxo Oncology, Inc. (1)  ·  Sanofi (1)

Countries

Australia (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  Germany (2)  ·  Greece (2)  ·  India (2)  ·  Israel (2)  ·  Italy (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  Spain (2)

Results publications

PMID 34292174, PMID 35969032, PMID 37870969, PMID 39694978, PMID 40617171

NIH funding

2019 (1)